• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025

Opinion
Video

A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.

Related Videos
Darla chapman, DNP
4 Experts are featured in this series
4 Experts are featured in this series
Rebecca Spain, MD
Jonathan Strober, MD, Benioff Children's Hospital
5 Experts are featured in this series.
5 Experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.